SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES

(19)

(11)

EP 1 727 809 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	29.10.2008 Bulletin 2008/44

(45)	Mention of the grant of the patent:
	11.06.2008 Bulletin 2008/24

(21)	Application number: 05706819.9

(22)	Date of filing: 09.03.2005

(51)

International Patent Classification (IPC):

C07D 295/12^(2006.01)
C07D 279/12^(2006.01)
A61K 31/4406^(2006.01)
A61K 31/5355^(2006.01)

C07D 265/06^(2006.01)
C07D 417/04^(2006.01)
A61K 31/541^(2006.01)
A61P 25/22^(2006.01)

(86)	International application number:
	PCT/DK2005/000159

(87)	International publication number:
	WO 2005/087754 (22.09.2005 Gazette 2005/38)

(54)	SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES SUBSTITUIERTE MORPHOLIN- UND THIOMORPHOLINDERIVATE DERIVÉS DE MORPHOLINE ET DE THIOMORPHOLINE SUBSTITUÉS

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA HR LV MK YU

(30)

Priority:

12.03.2004 DK 200400412
12.03.2004 US 552574 P

(43)	Date of publication of application:
	06.12.2006 Bulletin 2006/49

(60)	Divisional application:
	08007169.9 / 1947093

(73)	Proprietor: H. Lundbeck A/S
	2500 Valby-Copenhagen (DK)

(72)	Inventors:
	WENZEL TORNØE, Christian DK-2300 Copenhagen S (DK) ROTTLÄNDER, Mario DK-2670 Greve (DK) KHANZHIN, Nikolay DK-3050 Humlebaek (DK) RITZÉN, Andreas DK-2720 Vanløse (DK) WATSON, William Patrick DK-2720 Vanløse (DK)

(56)

References cited: :

WO-A-02/49628
US-A1- 2001 049 444

WO-A-02/066036

MAIN M J ET AL: "MODULATION OF KCNQ2/3 POTASSIUM CHANNELS BY THE NOVEL ANTICONVULSANT RETIGABINE" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 58, no. 2, August 2000 (2000-08), pages 253-262, XP000972245 ISSN: 0026-895X
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; BRN 6233316 1993, XP002330358 & VERMA M AL: ARCH PHARM (WEINHEIM W GER), vol. 315, no. 7, 1982, pages 358-363,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).